Bayer further expands global incubator network with Bayer Co.Lab Berlin and welcomes MyoPax as first resident

Investment underscores Bayer´s commitment to creating a leading life science ecosystem for innovative therapies in Berlin

02-Dec-2024 - Bayer announced the inauguration of its new life science incubator Bayer Co.Lab Berlin, located on the Global Headquarters Campus of Bayer’s Pharmaceuticals Division, near world-renowned research and clinical institutions. MyoPax GmbH, a Berlin-based start-up company specializing in muscle ...

Hope for the treatment of people with severe burns

Researchers are developing an innovative drug to prevent the rejection of donor skin grafts.

19-Nov-2024 - When people suffer severe burns, there is not only a risk of infection in the wound. The high loss of fluid can also result in life-threatening circulatory shock. Therefore, the destroyed skin must be replaced as quickly as possible. Ideally, the wounds are treated with the patient's own skin ...

Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

Collaboration between medac and start-up chiron to develop organ-on-chip technology

Further development and establishment of animal free testing methods for the pharmaceutical industry

12-Nov-2024 - Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further ...

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery

28-Oct-2024 - QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one ...

A “chemical ChatGPT” for new medications

AI learns chemical connections

25-Oct-2024 - Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model – a kind of ChatGPT for molecules. Following a training phase, the AI was able to exactly reproduce the chemical ...

New drugs from toxic birds

Investigation of the symbiosis between bacteria and birds leads to the discovery of new natural products with antimicrobial properties

10-Oct-2024 - Bacteria are a valuable source for the discovery of natural products that can be used for the development of new drugs. A HIPS research team has now identified two new classes of active substances with antimicrobial properties from bacteria that live in symbiosis with a toxic bird. This strategy ...

Innovative approach to treat autism spectrum disorders

University of Basel spin-off Translation-X receives Venture Kick funding

08-Oct-2024 - In 2022, Dr. Özgür Genç together with Professor Peter Scheiffele from the Biozentrum, University of Basel, founded the startup Translation-X with the goal of developing novel therapeutics for autism spectrum disorders. They have now received 150’000 Swiss Francs investment from the Venture Kick ...

€1.3M pre-seed funding for Lucid Genomics

Startup will use funds to fine-tune their AI models for diagnostics and biomarker discovery

05-Sep-2024 - The Berlin-based startup Lucid Genomics, a spin-off from the Max Planck Institute for Molecular Genetics and the Institute of Medical Genetics and Human Genetics at the Charité - Universitätsmedizin Berlin, has raised €1.3 million in pre-seed funding in a funding round led by Caesar Ventures, ...

Scientists Unravel Life-saving Effect of Dexamethasone in COVID-19

New approach for targeted drug development

05-Jul-2024 - Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at the DZNE and Charité – Universitätsmedizin Berlin have now discovered how the cortisone compound influences the impaired inflammatory response ...